LB PHARMACEUTICALS INC (LBRX)
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXHealthcare · Biotechnology
-1.12%$39.70
AH$41.19+3.75%vs close
Mkt Cap$1.28B
Float24.22M
O/S32.26M
Vol
$ Vol
RVOL
Inst Own92.5%
SI23.0%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$25.2M
Total Assets$312.93M
Free Cash Flow-$35.26M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$3.57M
Total Equity$301.31M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in LBRX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$312.93M
Liabilities$11.62M
Accounts Receivable$0
Accounts Payable$2.13M
Inventory$0
PP&E (Net)$3.73M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - |
| Research and Development | $16.74M | $51.17M | $7.84M | $1.35M |
| Selling, General, and Administrative | $13.66M | $13.66M | $3.53M | $1.46M |
| Other | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $30.4M | $64.83M | $11.38M | $2.81M |
| Operating Income (EBIT) | -$30.4M | -$64.83M | -$11.38M | -$2.81M |
| Operating Margin | - | - | - | - |
| Interest Expense | $0 | $0 | $4.83M | $2.15M |
| Interest Income | $3.92M | $1.72M | $811K | $73K |
| Other Income (Expense) | $5.2M | $1.73M | $5.1M | -$11.54M |
| Income Before Tax (EBT) | -$25.2M | -$63.1M | -$6.27M | -$14.35M |
| Income Tax Expense | $1K | $1K | $1K | $1K |
| Net Income | -$25.2M | -$63.1M | -$6.28M | -$14.35M |
| Net Income Margin | - | - | - | - |
| Supplementary Data | ||||
| EPS | -1.00 | -17.83 | -1.77 | -4.05 |
| Diluted EPS | -1.00 | -17.83 | -1.77 | -4.05 |
| Weighted Average OS | 25.30M | 3.54M | 3.54M | 3.54M |
| EBITDA | -$24.88M | -$63.01M | -$1.45M | -$12.19M |
| EBITDA Margin | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $250.17M | $22.98M | $14.98M | $21.4M |
| Short-Term Investments | $45.04M | $5.02M | $28.31M | $0 |
| Cash and Short-Term Investments | $295.21M | $28M | $43.29M | $21.4M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $11.23M | $132K | $26K | $9K |
| Total Current Assets | $308.43M | $28.88M | $45.63M | $21.49M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $3.73M | $4.16M | $23K | $3K |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $770K | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $498K | $0 | $0 |
| Total Long-Term Assets | $4.5M | $4.66M | $23K | $3K |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $312.93M | $33.53M | $45.66M | $21.49M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $2.13M | $2.32M | $1.39M | $156K |
| Short-Term Debt | $730K | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $2.9M | $2.24M | $798K | $221K |
| Total Current Liabilities | $7.44M | $8.11M | $2.61M | $469K |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $24.15M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $1.34M | $116.76M | $77.52M | $25.69M |
| Total Long-Term Liabilities | $4.18M | $119.98M | $77.52M | $49.84M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $11.62M | $128.09M | $80.13M | $50.3M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3K | $1K | $1K | $1K |
| Retained Earnings | -$129.53M | -$104.32M | -$41.22M | -$34.95M |
| Comprehensive Income & Other | $168K | $111K | $274K | $0 |
| Other Stockholders' Equity | $430.83M | $9.77M | $6.75M | $6.13M |
| Total Equity | $301.31M | -$94.55M | -$34.47M | -$28.81M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $312.93M | $33.53M | $45.66M | $21.49M |
| Supplementary Data | ||||
| Total Debt | $3.57M | $3.7M | $0 | $24.15M |
| Net Debt | -$246.6M | -$19.27M | -$14.98M | $2.74M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$25.2M | -$63.1M | -$6.28M | -$14.35M |
| Depreciation & Amortization | $321K | $91K | $4K | $2K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $0 | $3.16M | $295K | $431K |
| Changes in Working Capital: | ||||
| Accounts Receivable | -$268K | $114K | -$154K | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | -$910K | $0 | $0 | $0 |
| Other Working Capital | -$12.47M | $3.2M | -$1.16M | $86K |
| Total Working Capital Change | -$13.65M | $3.31M | -$1.31M | $86K |
| Other Non-Cash Items | $3.33M | $3.48M | -$4.8M | $11.1M |
| Net Cash from Operating | -$35.21M | -$53.05M | -$12.09M | -$2.73M |
| Investing Activities | ||||
| Capital Expenditures | -$52K | -$769K | -$25K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$44.84M | -$29.75M | -$33.98M | $0 |
| Sales of Investments | $5M | $53.75M | $6M | $123K |
| Other Investing Activities | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$39.89M | $23.23M | -$28.01M | $123K |
| Financing Activities | ||||
| Debt Repaid | - | - | -$725K | -$25M |
| Common Stock Issuance | $302.56M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$1.69M | -$2.05M | -$2.95M |
| Net Cash from Financing | $302.56M | $38.31M | $33.68M | $22.96M |
| Forex Effect | -$272K | $0 | $0 | $0 |
| Net Change in Cash | $227.19M | $8.5M | -$6.42M | $20.36M |
| Supplementary Data | ||||
| Operating Cash Flow | -$35.21M | -$53.05M | -$12.09M | -$2.73M |
| Capital Expenditure | -$52K | -$769K | -$25K | $0 |
| Free Cash Flow | -$35.26M | -$53.82M | -$12.12M | -$2.73M |
| Cash at Beginning | $22.98M | $14.98M | $21.4M | $1.05M |
| Cash at End | $250.17M | $23.48M | $14.98M | $21.4M |